Intro: In 2018, Julia Vitarello’s daughter Mila became the face of a revolutionary approach to medicine—a drug custom-made for her unique genetic mutation. That success sparked a vision: create such bespoke therapies for countless others. But the path from a single miracle to scalable solutions is fraught with scientific, regulatory, and financial obstacles. Now, after one startup faltered, Vitarello is launching a new biotech to turn that vision into reality. Here are ten key things you need to know about this daring journey.
1. The Story of Mila and Her Bespoke Medicine
Mila Makovec was born with a rare, fatal neurological disorder caused by a single mutation in the CLCN6 gene. Desperate for a cure, her mother Julia Vitarello partnered with researchers at Boston Children’s Hospital. They created milasen—a tailor-made antisense oligonucleotide therapy designed to correct Mila’s specific genetic error. The drug, delivered through a spinal injection, stabilized Mila’s condition and made headlines worldwide as a proof-of-concept for personalized genomic medicine. It remains one of the most famous examples of an “n-of-1” therapy, showing that even one patient can inspire a paradigm shift.
2. Julia Vitarello’s Journey from Parent to Entrepreneur
Vitarello, a former businesswoman with no scientific background, transformed her grief into advocacy. After Mila’s therapy succeeded, she founded EveryONE Medicines in 2019, aiming to systematically create similar customized drugs for patients with ultra-rare mutations. Her hands-on involvement—connecting families, scientists, and regulators—demonstrated that patient-led initiatives could drive innovation. The experience taught her the critical gaps in funding, manufacturing, and regulatory pathways that now shape her new venture.
3. The Promise of N-of-1 Therapies
Individualized medicines like milasen represent a radical departure from blockbuster drugs. Instead of treating thousands, they target a single patient’s unique molecular flaw. This approach holds hope for thousands of people with ultrarare genetic conditions—many of whom have no treatment options. Advances in gene sequencing and antisense technology make it increasingly feasible to design and test such drugs in months, not years. However, the economic model remains challenging: how do you justify the cost of developing a drug for one person?
4. The FDA’s Evolving Stance on Customized Therapies
In 2021, the U.S. Food and Drug Administration released draft guidance encouraging the development of individualized antisense therapies. But according to Vitarello, the guidance stopped short of creating a clear, workable regulatory pathway for companies to secure investment. Without predictable parameters for safety, efficacy, and manufacturing, venture capital stayed on the sidelines. This regulatory uncertainty was a key factor in EveryONE Medicines’ inability to attract long-term financing, ultimately leading to its dissolution.
5. Why EveryONE Medicines Folded
EveryONE Medicines was founded to industrialize the process of creating custom therapies, but it could not sustain momentum. Vitarello cited insufficient FDA guidance—despite the agency’s supportive intent—as the primary reason investors lost confidence. The company needed a clear reimbursement model and a path to scale manufacturing, but without regulatory clarity, the risk was too high. The closure was a bitter blow to the community, but it also clarified the structural changes needed for future success.
6. The New Biotech: A Second Act
Undeterred, Vitarello is now assembling a new biotech company—name yet to be announced—to tackle the same challenge with a more refined strategy. Collaborating with scientists who pioneered milasen, she aims to build a platform that can design, test, and manufacture personalized therapies at a fraction of current costs. The new venture will incorporate lessons from EveryONE’s failure, focusing on flexible regulatory engagement, lean operations, and partnerships with academic medical centers.
7. The Hurdle of Scaling Production
Creating one tailor-made drug is labor-intensive; making hundreds or thousands requires a complete rethinking of production. Each n-of-1 drug must be synthesized, quality-tested, and administered under strict oversight. Current manufacturing methods are designed for large batches, not single doses. Vitarello’s new company plans to leverage automated laboratory techniques and modular production lines that can quickly switch between different molecular designs—a kind of just-in-time manufacturing for precision medicine.
8. The Funding Challenge: A New Approach
Traditional venture capital shies away from therapies that can’t guarantee blockbuster returns. Vitarello and her team are therefore exploring alternative financing: philanthropic grants, crowdfunding, and so-called impact investment funds that prioritize social benefit over high margins. They are also engaging with patient advocacy groups and rare disease foundations that have long supported early-stage research. The goal is to build a sustainable nonprofit or low-profit business model that aligns with the mission rather than maximizing profit.
9. The Role of Patient Advocacy and Community
Mila’s story galvanized a grassroots movement of families desperate for similar breakthroughs. Vitarello’s new company will embed these families directly into the research process—from identifying mutations to providing real-world data on drug effectiveness. The model treats patients not as passive recipients but as active partners in drug development. This community-centric approach could reduce costs and accelerate timelines by bypassing traditional clinical trial bottlenecks.
10. What the Future Holds
If Vitarello succeeds, the biotech landscape could shift profoundly. A scalable framework for n-of-1 therapies would empower physicians to treat the “unreatable” and force regulators to adapt. The next few years will be critical: the new company must secure funding, demonstrate feasibility in a pilot project, and continue lobbying the FDA for clearer guidance. Mila is now a teenager, and her legacy may be not just one drug, but a blueprint for countless more personalized miracles.
Conclusion: Julia Vitarello’s journey from grieving mother to serial entrepreneur encapsulates both the promise and the pain of radical innovation in medicine. The collapse of EveryONE Medicines could have ended her quest, but instead it has sharpened her resolve. Her new biotech represents a second chance—for herself, for Mila, and for the thousands of families hoping that personalized medicine will one day become ordinary, not miraculous. The road ahead is steep, but if anyone can navigate it, it’s someone who has already achieved the impossible once.